GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: compound 1 [WO2024076985A2] [2] | PRT-3789
Compound class:
Synthetic organic
Comment: The structure presented here is claimed in patent WO2024076985A2 as a SMARCA2-selective degrader [2]. This same chemical structure was disclosed as Prelude Therapeutics' PRT3789 during the 'First Time disclosures' session at the ACS Spring 2025 meeting in San Diego. In patent US20240018158A1 Prelude Therapeutics claim degraders that interact with the SMARCA2 bromodomain, and E3 ubiquitin ligase to promote ubiquitin-mediated degradation. PRT3789 is one of these claims, although it difficult to ascertain which of the exemplar compounds is the exact stereoisomeric match to PRT3789. PRT3789 utilises a VHL-based E3 ligase binding moiety.
In therapeutic terms, reducing/inhibiting SMARCA2 is considered as a novel anti-tumour intervention [1], notably to exploit synthetic lethality in cancers that are SMARA4 deficient and that switch dependence to SMARCA2 for survival. |
|
|||||||||||||||||||||||||||||||||||
For advanced searching click here to open chemical structure editor
